Copernicus Podmiot Leczniczy Sp. z o.o.

The Oddział Neurologiczny at Copernicus Podmiot Leczniczy focuses on advancing treatments for disorders of the brain and nerves, with a particular emphasis on seizure disorders and demyelinating disease.

• Investigation of new oral agents for primary generalized tonic-clonic seizures
• Evaluation of therapies targeting focal-onset seizures
• Studies on disease‑modifying strategies for relapsing multiple sclerosis

Researchers at the Gdańsk site are testing innovative compounds to reduce seizure frequency and to limit central nervous system inflammation in multiple sclerosis patients.

Clinical work in the cardiovascular field concentrates on preventing recurrent clot‑related events after an acute brain injury, aiming to improve outcomes for patients who have suffered a stroke or a high‑risk transient ischemic attack.

• Assessment of an oral FXIa inhibitor for reducing ischemic stroke recurrence
• Safety monitoring of major bleeding in participants receiving antiplatelet therapy
• Comparative analysis of clot‑prevention strategies following non‑cardioembolic stroke

The Gdańsk hospital collaborates with international partners to determine whether the new agent can safely lower the risk of further strokes while maintaining acceptable bleeding rates.

In the oncology portfolio, the center evaluates immunotherapy approaches for kidney cancer, seeking to improve long‑term survival after surgical removal of the tumor.

• Adjuvant treatment trial for renal cell carcinoma following nephrectomy
• Measurement of disease‑free survival with checkpoint inhibitor therapy
• Safety and tolerability profiling of pembrolizumab in the postoperative setting

The team at Copernicus Podmiot Leczniczy is dedicated to generating evidence that immune‑based regimens can reduce cancer recurrence and extend patient life expectancy.